Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 134.00 TWD
Change Today -5.50 / -3.94%
Volume 967.0K
3176 On Other Exchanges
As of 12:13 AM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

medigen biotechnology corp (3176) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/13/14 - 486.00
52 Week Low
08/22/14 - 105.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDIGEN BIOTECHNOLOGY CORP (3176)

Related News

No related news articles were found.

medigen biotechnology corp (3176) Related Businessweek News

No Related Businessweek News Found

medigen biotechnology corp (3176) Details

Medigen Biotechnology Corp. focuses on the development of therapeutics for liver diseases and cancers in Taiwan. Its product portfolio includes PI-88 for reducing tumor recurrence after surgical resection of early hepatocellular carcinoma (HCC); and Telomelysin, an oncolytic virotherapy for head and neck cancers, and HCC treatment. It is also developing MDCK cell-based H1N1 vaccines, which completed Phase I clinical trial and preclinical animal testing. In addition, the company offers human leukocyte antigen test diagnostic kits, as well as focuses on manufacturing H5N1 clinical lots and developing EV71 vaccine. The company was founded in 1999 and is based in Taipei City, Taiwan.

Founded in 1999

medigen biotechnology corp (3176) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medigen biotechnology corp (3176) Key Developments

Medigen Biotechnology Corp. Provides Additional Information on the Results of the Interim Analysis for the Phase III Patron Clinical Trial for PI-88

Medigen Biotechnology Corp. has provided additional information on the results of the interim analysis for the Phase III PATRON clinical trial for PI-88. The PATRON trial is a fully recruited randomised, placebo-controlled Phase III trial being conducted in Taiwan, South Korea, China and Hong Kong to confirm the safety and efficacy of PI-88 in the adjuvant treatment of hepatocellular carcinoma after surgical resection. The results of the interim analysis carried out on the Phase III clinical trial for PI-88 indicated that it did not meet the primary endpoint of Disease Free Survival, and that further analysis of the data will be conducted by an independent medical imaging company in the US, BioClinica. It is now expected that this analysis by BioClinica of the patients' CT and magnetic resonance data will be conducted by the end of the year, and will be an important reference for the efficacy of PI-88. Further, Medigen is continuing PI-88's Phase III PATRON clinical trial in 25 clinical centres. Medigen is expecting to complete the final analysis on the total targeted recurrent 218 patients in 2015, to ensure that a final analysis can be conducted on PI-88's compliance with various endpoints. Medigen has provided further information on the differences between this interim analysis and the final analysis expected in 2015. The efficacy endpoints for the Phase III PATRON clinical trial for PI-88 include: 1. Disease Free Survival; 2. Time To Recurrence; 3. Tumour Recurrence Rate; and 4. Overall Survival. The interim analysis mainly analysed the primary endpoint of Disease Free Survival, whereas the final analysis will analyse all of the efficacy endpoints to determine the complete safety and efficacy profile of PI-88. Both the interim and final analysis use the two-tailed P-value to determine the statistical difference between the treatment and placebo groups. The smaller the P-value, the more significant the difference, or the higher the efficacy. Generally, there is a significant difference when the P-value is lower than 0.05. In line with PI-88's Phase III trial protocol, the interim analysis was only based on 60% of the available data, and therefore the P-value was set very low at 0.01806, to demonstrate whether PI-88 meets the statistical significant difference. The final analysis will be conducted on the data from the total targeted recurrent 218 patients, and as such the statistical significant difference has been set at a P-value of 0.04148.

Medigen Presents at 2014 Asia Biotech Invest Conference, Jun-05-2014 10:20 AM

Medigen Presents at 2014 Asia Biotech Invest Conference, Jun-05-2014 10:20 AM. Venue: Sheraton Hong Kong Hotel & Towers, 20 Nathan Road, Kowloon, Hong Kong. Speakers: David Ma, Business Development Director.

Medigen Biotechnology Corp., Annual General Meeting, Jun 09, 2014

Medigen Biotechnology Corp., Annual General Meeting, Jun 09, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3176:TT 134.00 TWD -5.50

3176 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3176.
View Industry Companies

Industry Analysis


Industry Average

Valuation 3176 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 68.5x
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 56.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIGEN BIOTECHNOLOGY CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at